Treatment of hormone-refractory breast cancer: Apoptosis and regression of human tumors implanted in mice

Molecular Cancer Therapeutics

Volumn 5, Issue 9, 2006, Pages 2366-2377

  Aneja, Ritu ^a   Zhou, Jun ^b   Zhou, Binfei ^a   Chandra, Ramesh ^c   Joshi, Harish C ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NANKAI UNIVERSITY   (China)

^c UNIVERSITY OF DELHI   (India)

Author keywords

[No Author keywords available]

Indexed keywords

9 BROMONOSCAPINE; ANTINEOPLASTIC AGENT; CASPASE 3; CYTOCHROME C; DOXORUBICIN; HORMONE DERIVATIVE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NOSCAPINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER CELL CULTURE; CANCER REGRESSION; CARDIOTOXICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENCY; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME DEGRADATION; ENZYME RELEASE; ENZYME SUBSTRATE; FEMALE; GASTROINTESTINAL TOXICITY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; INHIBITION KINETICS; LIVER TOXICITY; LONGEVITY; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SPLEEN DISEASE; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BREAST NEOPLASMS; CASPASE 3; CELL MEMBRANE; COLLAGEN TYPE XI; CYTOCHROMES C; DIOXOLES; FEMALE; HUMANS; IN SITU NICK-END LABELING; ISOQUINOLINES; MEMBRANE POTENTIALS; MICE; MICE, INBRED BALB C; MICE, NUDE; MITOCHONDRIAL MEMBRANES; MITOTIC SPINDLE APPARATUS; NEOPLASMS, HORMONE-DEPENDENT; NOSCAPINE; PROTO-ONCOGENE PROTEINS C-BCL-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33749555016     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-06-0205     Document Type: Article

References (66)

1. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994;29:127-38.
2. Jatoi I, Anderson WF, Rao SR, Devesa SS. Breast cancer trends among black and white women in the United States. J Clin Oncol 2005;23:7836-41.
3. Bange J, Zwick E, Ullrich A. Molecular targets for breast cancer therapy and prevention. Nat Med 2001;7:548-52.
4. Medina D. Mammary developmental fate and breast cancer risk. Endocr Relat Cancer 2005;12:483-95.
5. Anderson TJ. Pathological studies of apoptosis in the normal breast. Endocr Relat Cancer 1999;6:9-12.
6. Rosfjord EC, Dickson RB. Growth factors, apoptosis, and survival of mammary epithelial cells. J Mammary Gland Biol Neoplasia 1999;4:229-37.
7. Bentrem DJ, Jordan VC. Role of antiestrogens and aromatase inhibitors in breast cancer treatment. Curr Opin Obstet Gynecol 2002;14:5-12.
8. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991;83:1797-805.
9. Hortobagyi GN, Holmes FA. Single-agent paclitaxel for the treatment of breast cancer: an overview. Semin Oncol 1996;23:4-9.
10. Nabholtz JM, Gelmon K, Bontenbal M, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67.
11. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 2005;10:665-85.
12. He L, Orr GA, Horwitz SB. Novel molecules that interact with microtubules and have functional activity similar to taxol. Drug Discov Today 2001;6:1153-64.
13. Weisenberg RC. Microtubule formation in vitro in solutions containing low calcium concentrations. Science 1972;177:1104-5.
14. Miki-Noumura T, Mori H. Polymerization of tubulin: the linear polymer and its side-by-side aggregates. J Mechanochem Cell Motil 1972;1:175-88.
15. Nogales E. Structural insights into microtubule functions. Annu Rev Biophys Biomol Struct 2001;30:397-420.
16. Sammak PJ, Borisy GG. Direct observation of microtubule dynamics in living cells. Nature 1998;332:724-6.
17. Mitchison TJ. Microtubule dynamics and kinetochore function in mitosis. Annu Rev Cell Biol 1988;4:527-49.
18. Mitchison TJ, Kirschner M. Dynamic instability of microtubule growth. Nature 1984;312:237-42.
19. Mitchison TJ, Kirschner M. Microtubule assembly nucleated by isolated centrosomes. Nature 1984;312:232-7.
20. Mitchison TJ, Evans LM, Schulze E, Kirschner M. Properties of the kinetochore in vitro. I. Microtubule nucleation and tubulin binding. Cell 1986;45:515-27.
21. Kirschner M, Mitchison T. Beyond self-assembly: from microtubules to morphogenesis. Cell 1986;45:329-42.
22. Schnapp BJ, Vale RD, Sheetz MP, Reese TS. Microtubules and the mechanism of directed organelle movement. Ann N Y Aced Sci 1986;466:909-18.
23. Joshi HC. Microtubule dynamics in living cells. Curr Opin Cell Biol 1998;10:35-44.
24. Vendre DD, Kornebusch P, Borisy GG. Molecular biology of the cytoskeleton. Borisy GG, Cleveland DW, Murphy DB, editors. New York: Cold Spring Harbor Laboratory; 1984:3-16.
25. Salmon ED, Leslie RJ, Saxton WM, Karow ML, McIntosh JR. Spindle microtubule dynamics in sea urchin embryos: analysis using a fluorescein-labeled tubulin and measurements of fluorescence redistribution after laser photobleaching. J Cell Biol 1984;99:2165-74.
26. McIntosh JR, Koonce MP. Mitosis. Science 1989;246:622-8.
27. Li R, Murray AW. Feedback control of mitosis in budding yeast. Cell 1991;66:519-31.
28. Hoyt MA, Totis L, Roberts BT. S. cerevisiae genes required for cell cycle arrest in response to loss of microtubule function. Cell 1991;66:507-17.
29. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004;4;253-65.
30. Zhou J, Giannakakou P. Targeting microtubules for cancer chemotherapy. Curr Med Chem Anticancer Agents 2005;5:65-71.
31. ten Tije AJ, Smorenburg CH, Seynaeve C, et al. Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. Eur J Cancer 2004;40:352-7.
32. Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu Rev Mad 1997;48:353-74.
33. Orr GA, Verdier-Pinard P, McDaid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene 2003;22:7280-95.
34. Giannakakou P, Sackett DL, Kang YK, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem 1997;272:17118-25.
35. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002;2:48-58.
36. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resist Updat 2001;4:3-8.
37. Monzo M, Rosell R, Sanchez JJ, et al. Paclitaxel resistance in non-small-cell lung cancer associated with β-tubulin gene mutations. J Clin Oncol 1999;17:1786-93.
38. Chopin V, Toillon RA, Jouy N, Le Bourhis X. p21(WAF1/CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004;23:21-9.
39. Ye K, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Aced Sci U S A 1998;96:1601-6.
40. Loder RE. Safe reduction of the cough reflex with noscapine. A preliminary communication on a new use for an old drug. Anaesthesia 1969;24:355-8.
41. Ke Y, Ye K, Grossniklaus HE, Archer DR, Joshi HC, Kapp JA. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer Immunol Immunother 2000;49:217-25.
42. Joshi HC, Zhou J. Noscapine and analogues as potential chemotherapeutic agents. Drug News Perspect 2000;13:543-6.
43. Ye K, Zhou J, Landen JW, Bradbury EM, Joshi HC. Sustained activation of p34(cdc2) is required for noscapine-induced apoptosis. J Biol Chem 2001;276:46697-700.
44. Zhou J, Panda D, Landen JW, Wilson L, Joshi, HC. Minor alteration of microtubule dynamics causes loss of tension across kinetochore pairs and activates the spindle checkpoint. J Biol Chem 2002;277:17200-8.
45. Zhou J, Gupta K, Yao J, et al. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinase-mediated apoptosis in response to noscapine. J Biol Chem 2002;277:39777-85.
46. Landen JW, Hau V, Wang M, et al. Noscapine crosses the blood-brain barrier and inhibits glioblastorna growth. Clin Cancer Res 2004;10:5187-201.
47. Checchi PM, Nettles JH, Zhou J, Snyder JP, Joshi HC. Microtubule-interacting drugs for cancer treatment. Trends Pharmacol Sci 2003;24:361-5.
48. Zhou J, Gupta K, Aggarwal S, et al. Brominated derivatives of noscapine are potent microtubule-interfering agents that perturb mitosis and inhibit cell proliferation. Mol Pharmacol 2003;63:799-807.
49. Kilker RL, Hartl MH, Rutherford TM, Planas-Silva MD. Cyclin D1 expression is dependent on estrogen receptor function in tamoxifen-resistant breast cancer cells. J Steroid Biochem Mol Biol 2004;92:63-71.
50. Skehan P, Storeng R, Scudiero D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 1990;82:1107-12.
51. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998;281:1322-6.
52. Daniel PT. Dissecting the pathways to death. Leukemia 2000;14:2035-44.
53. Lotem J, Sachs L. Regulation by bcl-2, c-myc, and p53 of susceptibility to induction of apoptosis by heat shock and cancer chemotherapy compounds in differentiation-competent and -defective myeloid leukemic cells. Cell Growth Differ 1993;4:41-7.
54. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993;81:151-7.
55. Bargou RC, Wagener C, Bommert K, et al. Overexpression of the death-promoting gene bax-α which is downregulated in breast cancer restores sensitivity to different apoptotic stimuli and reduces tumor growth in SCID mice. J Clin Invest 1996;97:2651-9.
56. Radetzki S, Kohne CH, von Haefen C, et al. The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene 2002;21:227-38.
57. Green DR, Reed JC. Mitochondria and apoptosis. Science 1998;281:1309-12.
58. Liu X, Kim CN, Yang J, Jemmerson R, Wang X. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell 1996;86:147-57.
59. Li P, Nijhawan D, Budihardjo I, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997;91:479-89.
60. Kaufmann SH, Desnoyers S, Ottaviano Y, Davidson NE, Poirier GG. Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 1993;53:3976-85.
61. Maderna P, Godson C. Phagocytosis of apoptotic cells and the resolution of inflammation. Biochim Biophys Acta 2003;1639:141-51.
62. Aneja R, Zhou J, Vangapandu SN, Zhou B, Chandra R, Joshi HC. Drug-resistant T-lymphoid tumors undergo apoptosis selectively in response to an antimicrotubule agent, EM011. Blood 2006;107:2486-92.
63. Banerjee A, Kasmala LT. Differential assembly kinetics of α-tubulin isoforms in the presence of paclitaxel. Biochem Biophys Res Commun 1998;245:349-51.
64. Banerjee A, Engelborghs Y, D'Hoore A, Fitzgerald TJ. Interactions of a bicyclic analog of colchicine with β-tubulin isoforms αβ(II), αβ(III) and αβ(IV). Eur J Biochem 1997;246:420-4.
65. Ranganathan S, Dexter DW, Benetatos CA, Chapman AE, Tew KD, Hudes GR. Increase of β(III)- and β(IVa)-tubulin isotopes in human prostate carcinoma cells as a result of estramustine resistance. Cancer Res 1996;56:2584-9.
66. Zhou J, Liu M, Luthra R, et al. EM012, a microtubule-interfering agent, inhibits the progression of multidrug-resistant human ovarian cancer both in cultured cells and in athymic nude mice. Cancer Chemother Pharmacol 2005;55:461-5.